Compare NAD & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAD | CDNA |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | N/A | 2007 |
| Metric | NAD | CDNA |
|---|---|---|
| Price | $9.80 | $63.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $30.33 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $9.75 | $13.95 |
| 52 Week High | $12.31 | $65.50 |
| Indicator | NAD | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 13.88 | 74.55 |
| Support Level | N/A | $17.26 |
| Resistance Level | $11.97 | N/A |
| Average True Range (ATR) | 0.20 | 2.90 |
| MACD | -0.09 | 0.92 |
| Stochastic Oscillator | 4.02 | 87.01 |
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.